Clinical Trials Browser

INDUSTRY × Neoplasms × efatutazone × Clear all

NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

15 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT00408434 2020-10-19

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Phase 1 Completed

32 enrolled 17 charts

Neoplasms

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

16 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms